openPR Logo
Press release

Hereditary Angioedema Market : Global Forecast over 2025

09-27-2017 09:47 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Hereditary Angioedema Market : Global Forecast over 2025

As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016.

Superior Healthcare Facilities Makes North America Market Leader

Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor, among others including conventional and pipeline. The C1 esterase inhibitor can be further divided into drugs such as Cinryze, Berinert, and Ruconest. Among them, C1 esterase inhibitor, accounted for more than half the share in the market in 2016 and going forward too, the segment is slated to dominate the market on account of its use in treatment of prophylactic and severe HAE attack. The emergence of novel products will aid the segment to hold on to its leading share in the future.

View and Download TOC of Hereditary Angioedema Market Research Report@ https://www.transparencymarketresearch.com/report-toc/17135

Geography-wise, North America, Europe, and Rest of the World are the key regions in the global hereditary angioedema market. At present, North America accounts for a leading position and in the upcoming years too is expected to retain its dominant share by rising at a healthy 8.3% CAGR between 2017 and 2025. This is because of the superior healthcare infrastructure and strong support from public and private sector in terms of reimbursements. Increasing knowledge about HAE among patients has resulted better methods of diagnosis of HAE and adoption of specialty drugs for treatment of HAE – this is also expected to catalyze growth in the market.

Progress in Diagnosis Catalyzing Growth in Market

Hereditary angioedema is a rare disease that is estimated to affect 1 in 30,000 to 1 in 50,000 people worldwide. Hereditary angioedema is often mistaken for common allergic reactions and abdominal pain due to lack of awareness both among physicians and patients. It is estimated that around 40% of the affected patient are diagnosed correctly for HAE in the U.S. and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.

“Specialty hereditary angioedema drugs are offered orphan drug designation across the markets which offers them market exclusivity and several incentives in the regional markets. The frequency and severity of HAE attacks is found to be increased with triggers such as stress, anxiety, minor surgeries, hormone replacement therapies and ACE inhibitors used for treatment of hypertension. According to World Allergy Organization, an estimated 40 million people are receiving ACE inhibitor treatment annually. The projected rise in incidences of HAE attacks is estimated to drive growth for global hereditary angioedema market during the forecast period from 2017 to 2025,” explains the lead analyst of the TMR report.

Request and Download Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17135

Acting as a hindrance to the market, on the other hand, is a few approved specialty hereditary angioedema drugs which makes them highly expensive.

Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc.

Buy Full Hereditary Angioedema Market Report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=17135

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hereditary Angioedema Market : Global Forecast over 2025 here

News-ID: 742444 • Views: 428

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for HAE

MENTAL HEALTH IN THE SPOTLIGHT AT HAE EHA CONFERENCE
Members, non-members and exhibitors attending HAE EHA’s annual conference at Holywell Park in Loughborough were given an ideal opportunity to assess and improve their strategies for dealing with mental health in the workplace by expert speakers on this growing issue. It is estimated mental health problems blight one in four of the UK population (http://www.hse.gov.uk/stress/mental-health.htm), a figure replicated last year in the construction industry according to a survey by Construction News’
Hereditary Angioedema Market is propelled by rise in hereditary angioedema (HAE) …
Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016. Read Report Overview: https://www.transparencymarketresearch.com/hereditary-angioedema-market.html Superior Healthcare
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) Clinical …
Market Research Hub includes new market research report "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) Clinical Trials Review, H2, 2017" to its huge collection of research reports. Request Free Sample Report- https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350242 Clinical trial report, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) clinical trials scenario. This report provides top line data relating
Hereditary Angioedema (HAE) Market - Future Scope Detailed Analysis to 2024
Global Hereditary Angioedema (HAE) Market: Overview Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal. View Report @ http://www.transparencymarketresearch.com/hereditary-angioedema-market.html For the treatment of hereditary angioedema, currently there are
Hereditary Angioedema (HAE) - Pipeline Review, Trends, and Forecast Report 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Hereditary Angioedema (HAE) - Pipeline Review, H1 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196650 Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -
Hereditary Angioedema (HAE) Market Research Report | Forecast up to 2024
Global Hereditary Angioedema (HAE) Market: Overview Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal. For the treatment of hereditary angioedema, currently there are no medications